HOME >> MEDICINE >> NEWS
Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

(PHILADELPHIA) -- The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial. The findings, if backed by larger studies, could have important implications for designing personalized treatments for this very dangerous type of prostate cancer, the researchers say.

The team of scientists including first author Jose Moreno, M.D., clinical associate professor of urology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and the Kimmel Cancer Center at Jefferson looked at circulating tumor cells (CTCs) in 240 men with metastatic prostate cancer that failed hormone-depletion therapy. They compared levels prior to chemotherapy and after two to five weeks of treatment. They found that those men with more than five tumor cells per blood sample had a worse prognosis than those who had fewer cells. One half of the patients with more than five CTCs lived at least 10 months, whereas half of the men with fewer tumor cells lived substantially longer 21 months.

Dr. Moreno presents the trials findings June 4, 2007 at the annual meeting of the American Society of Clinical Oncology in Chicago.

The results of the 65-site trial also showed that those patients who underwent chemotherapy and whose CTC number went down fared better and had a more favorable prognosis. That is, the level of response to chemotherapy was reflected in the CTC level, notes Dr. Moreno. The numbers held up even after up to 20 weeks of treatment. If chemotherapy doesnt reduce the CTC level, its information that enables the physician to change the drug regimen or perhaps stop treatment, he says.

Dr. Moreno notes that the prostate specific antigen has been a powerful biomarker for cancer presence and a useful way to gauge treatment effectiveness for years, though it has some flaws. He thinks that th
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
4-Jun-2007


Page: 1 2

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. ENDEAVOR III Trial reports key findings on new-generation stent
4. NIH names Clinical Trial Units for the Microbicide Trials Network
5. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
6. The Public Library of Science launches the new open access journal PLoS Clinical Trials
7. Trial shows vaccine against cervical cancer provides long-term protection
8. Trial shows malaria vaccine could protect young children from disease for 18 months
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2019)... ... January 11, 2019 , ... ... endometriosis to remove inflammatory endometriosis tissue, relieve pain, and help restore fertility. , ... In more common cases, tissue typically grows on the ovaries, fallopian tubes, and ...
(Date:1/10/2019)... ... January 10, 2019 , ... Net-Translators, ... partnered with MD101, a regulatory consulting company that serves the medical industry. The ... servicing companies in the medical device and healthcare industries. Based in France, they ...
(Date:1/10/2019)... SAN DIEGO (PRWEB) , ... January 10, 2019 ... ... and education on CBD and Hemp companies, partners with NeuCana Companion to educate ... pet owners. , CBD is believed to help calm pain and anxiety related ...
(Date:1/8/2019)... ... January 08, 2019 , ... ... now have Norepinephrine in their patent-pending vial-based configuration, Snap-N-Go®, available to order ... are not commercially available) deliver a precise dose when introduced into a ...
(Date:1/7/2019)... ... January 07, 2019 , ... byte is thrilled ... to improve smiles and physical health across the nation. byte is an at-home ... a brighter and straighter smile being treated by leading orthodontists and the latest ...
Breaking Medicine News(10 mins):
(Date:1/10/2019)... ... January 10, 2019 , ... Mindray, a leading developer ... Delivery platform, providing a modular, state-of-the-art family of anesthesia solutions. The new ... its unwavering commitment to perioperative care. , “The recently launched Advantage platform ...
(Date:1/10/2019)... ... 10, 2019 , ... Pelican BioThermal , the global ... under the leadership of Dominic Hyde, vice president of Credo™ on Demand. , ... shipper rental program allowing organizations to choose the shipper application that best fits ...
(Date:1/8/2019)... , ... January 08, 2019 , ... ... been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. ... System and demonstrated a commitment to exemplary care for men suffering from symptoms ...
Breaking Medicine Technology:
Cached News: